KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Capital Expenditures (2016 - 2024)

Arbutus Biopharma (ABUS) has disclosed Capital Expenditures for 12 consecutive years, with $86000.0 as the latest value for Q4 2024.

  • Quarterly Capital Expenditures changed N/A to $86000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $86000.0 through Sep 2025, down 10.42% year-over-year, with the annual reading at $182000.0 for FY2024, 81.94% down from the prior year.
  • Capital Expenditures hit $86000.0 in Q4 2024 for Arbutus Biopharma, up from $1000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $859000.0 in Q2 2023 to a low of $1000.0 in Q2 2024.
  • Historically, Capital Expenditures has averaged $161176.5 across 5 years, with a median of $91000.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: surged 857.58% in 2021 and later crashed 99.88% in 2024.
  • Year by year, Capital Expenditures stood at $152000.0 in 2020, then plummeted by 61.84% to $58000.0 in 2021, then skyrocketed by 131.03% to $134000.0 in 2022, then crashed by 76.12% to $32000.0 in 2023, then soared by 168.75% to $86000.0 in 2024.
  • Business Quant data shows Capital Expenditures for ABUS at $86000.0 in Q4 2024, $1000.0 in Q2 2024, and $95000.0 in Q1 2024.